Li Xiangpan, Chu Yuxin, Song Qibin, Hu Qinyong
Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.
J Oncol. 2022 May 28;2022:3308801. doi: 10.1155/2022/3308801. eCollection 2022.
The patients from the Surveillance, Epidemiology, and End Results (SEER) database were recruited to explore the incidence-based mortality and survival trends from 2000 to 2017. We further analyzed the differences in mortality and survival trends in these patients by sex and stage. We also used joinpoint software to evaluate the trends in annual percentage change (APC) for statistical significance.
14916 patients were collected, including 7801 (52.3%) male and 7115 (47.7%) female. We identified a single joinpoint at 2002. The overall incidence-based mortality of gastric SRC declined in America after 2002 (APC = -1.21, < 0.05). In stratified analysis by sex and stage, the incidence-based mortality rate was higher in males than females. After 2002, the mortality rate decreased significantly in male (APC = -1.68, < 0.05) and M0-stage patients (APC = -1.75, < 0.05). In survival trend analysis, the 2-year relative survival improved in M0-stage gastric SRC, especially for males (APC = 1.14, < 0.05). As for M1-stage patients, the 2-year relative survival significantly elevated in both male (APC = 3.87, < 0.05) and female (APC = 5.63, < 0.05) patients.
The incidence-based mortality of gastric SRC has declined, and survival has improved in America over time. These optimistic trends may be attributed to cancer screening implementation and advances in novel treatments in the past decades.
招募来自监测、流行病学和最终结果(SEER)数据库的患者,以探究2000年至2017年基于发病率的死亡率和生存趋势。我们进一步按性别和分期分析了这些患者死亡率和生存趋势的差异。我们还使用连接点软件评估年度百分比变化(APC)趋势的统计学显著性。
共收集到14916例患者,其中男性7801例(52.3%),女性7115例(47.7%)。我们在2002年确定了一个单一连接点。2002年后美国胃肉瘤样癌基于发病率的总体死亡率下降(APC = -1.21,P < 0.05)。在按性别和分期进行的分层分析中,男性基于发病率的死亡率高于女性。2002年后,男性(APC = -1.68,P < 0.05)和M0期患者(APC = -1.75,P < 0.05)的死亡率显著下降。在生存趋势分析中,M0期胃肉瘤样癌的2年相对生存率有所提高,尤其是男性(APC = 1.14,P < 0.05)。对于M1期患者,男性(APC = 3.87,P < 0.05)和女性(APC = 5.63,P < 0.05)患者的2年相对生存率均显著提高。
在美国,胃肉瘤样癌基于发病率的死亡率有所下降,生存情况随时间推移有所改善。这些乐观趋势可能归因于过去几十年癌症筛查的实施和新治疗方法的进步。